Clinical Trials Browser

Neoplasms, Plasma Cell × ibrutinib × 1 year × Clear all

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

14 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell